For research use only, not for therapeutic use.
HBX-41108（Cat No.:I007192）is a small molecule inhibitor designed to target the oncogenic protein MDM2, which negatively regulates the tumor suppressor p53. By inhibiting MDM2, HBX-41108 aims to restore p53 activity, promoting apoptosis in cancer cells that depend on MDM2 for survival. It has shown potential in preclinical studies for various cancers, including leukemia and solid tumors. This compound is being investigated for its efficacy in overcoming resistance to other therapies. Common side effects and safety profiles are still under evaluation in clinical trials, with a focus on optimizing treatment strategies for patients.
| Catalog Number | I007192 |
| CAS Number | 924296-39-9 |
| Synonyms | HBX 41108; HBX-41108; HBX41108; HBX 41,108; HBX-41,108; HBX41,108.;7-Chloro-9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile |
| Molecular Formula | C13H3ClN4O |
| Purity | ≥95% |
| Target | DUB |
| Solubility | Soluble in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | 7-chloro-9-oxoindeno[1,2-b]pyrazine-2,3-dicarbonitrile |
| InChI | InChI=1S/C13H3ClN4O/c14-6-1-2-7-8(3-6)13(19)12-11(7)17-9(4-15)10(5-16)18-12/h1-3H |
| InChIKey | BIGPXXAUSQLTQR-UHFFFAOYSA-N |
| SMILES | C1=CC2=C(C=C1Cl)C(=O)C3=NC(=C(N=C23)C#N)C#N |
| Reference | </br>1:Nicholson B, Suresh Kumar KG. The multifaceted roles of USP7: new therapeutic opportunities. Cell Biochem Biophys. 2011 Jun;60(1-2):61-8. doi: 10.1007/s12013-011-9185-5. Review. PubMed PMID: 21468693. |
